diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-819diaendo-819Research ArticleКардиологияCardiologyИзучение роли факторов роста фибробластов (bFGF, TGFbeta1), маркеров воспаления (IL-6, TNF-alpha, СRP) и конечных продуктов гликирования (AGE, RAGE) у пациентов с ишемической болезнью сердца и сахарным диабетом 2 типаbFGF and TGFbeta1 growth factors, inflammatory markers (IL-6, TNF-alpha, CRP) and advanced glycation end-products (AGE, RAGE) in patients with ischemic heart disease and type 2 diabetes mellitusИванниковаЕкатерина ВладимировнаIvannikovaEkaterina Vladimirovnadoc.ivannikova@gmail.comМелкозеровКонстантин ВладимировичMelkozerovKonstantin Vladimirovichdoc.ivannikova@gmail.comКалашниковВиктор ЮрьевичKalashnikovVictor Yur'evichdoc.ivannikova@gmail.comТерёхинСергей АнатольевичTerekhinSergey Anatol'evichdoc.ivannikova@gmail.comКононенкоИрина ВладимировнаKononenkoIrina Vladimirovnadoc.ivannikova@gmail.comСмирноваОльга МихайловнаSmirnovaOlga Mikhailovnadoc.ivannikova@gmail.comФГБУ Эндокринологический научный центрРоссияEndocrinology Research Centre, MoscowRussian Federation201305112013163Сахарный диабет6470Copyright © Иванникова Е.В., Мелкозеров К.В., Калашников В.Ю., Терёхин С.А., Кононенко И.В., Смирнова О.М., 20132013Иванникова Е.В., Мелкозеров К.В., Калашников В.Ю., Терёхин С.А., Кононенко И.В., Смирнова О.М.Ivannikova E.V., Melkozerov K.V., Kalashnikov V.Y., Terekhin S.A., Kononenko I.V., Smirnova O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/819факторы роста фибробластовсахарный диабетишемическая болезнь сердцаfibroblast growth factorsdiabetes mellitusischemic heart diseasesReferencesFlavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD. Fibroblasts as novel therapeutic targets in chronic inflammation. British Journal of Pharmacology. 2008;153(S1):S241-S246. DOI: http://dx.doi.org/10.1038/sj.bjp.0707487Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD. Fibroblasts as novel therapeutic targets in chronic inflammation. British Journal of Pharmacology. 2008;153(S1):S241-S246. DOI: http://dx.doi.org/10.1038/sj.bjp.0707487Yun Y-R, Won JE, Jeon E, Lee S, Kang W, Jo H, et al. Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration. Journal of Tissue Engineering. 2010 January 1, 2010;1(1). DOI: http://dx.doi.org/10.4061/2010/218142Yun Y-R, Won JE, Jeon E, Lee S, Kang W, Jo H, et al. Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration. Journal of Tissue Engineering. 2010 January 1, 2010;1(1). DOI: http://dx.doi.org/10.4061/2010/218142Шурыгина ИА, Шурыгин МГ, Аюшинова НИ, Каня ОВ. Фибробласты и их роль в развитии соединительной ткани. Сибирский медицинский журнал.2012;110(3):8-12. [Shurygina IA, Shurygin MG, Ayushinova NI, Kanya OV. Fibroblasts and their role in the development of connective tissue. Sibirskiy meditsinskiy zhurnal. 2012;110(3):8-12]Шурыгина ИА, Шурыгин МГ, Аюшинова НИ, Каня ОВ. Фибробласты и их роль в развитии соединительной ткани. Сибирский медицинский журнал.2012;110(3):8-12. [Shurygina IA, Shurygin MG, Ayushinova NI, Kanya OV. Fibroblasts and their role in the development of connective tissue. Sibirskiy meditsinskiy zhurnal. 2012;110(3):8-12]Keeley EC, Mehrad B, Strieter RM. Fibrocytes: Bringing new insights into mechanisms of inflammation and fibrosis. The international journal of biochemistry & cell biology. 2010 Apr;42(4): 535-542. DOI: http://dx.doi.org/10.1016/j.biocel.2009.10.014Keeley EC, Mehrad B, Strieter RM. Fibrocytes: Bringing new insights into mechanisms of inflammation and fibrosis. The international journal of biochemistry & cell biology. 2010 Apr;42(4): 535-542. DOI: http://dx.doi.org/10.1016/j.biocel.2009.10.014Chesney J, Metz C, Stavitsky AB, Bacher M, Bucala R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. Journal of immunology. 1998 Jan 1;160(1):419-425.Chesney J, Metz C, Stavitsky AB, Bacher M, Bucala R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. Journal of immunology. 1998 Jan 1;160(1):419-425.Hartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB journal. 2001 Oct;15(12):2215-2224. DOI: http://dx.doi.org/10.1096/fj.01-0049comHartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB journal. 2001 Oct;15(12):2215-2224. DOI: http://dx.doi.org/10.1096/fj.01-0049comConway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovascular Research. 2001 February 16, 2001;49(3):507-521. DOI: http://dx.doi.org/10.1016/S0008-6363(00)00281-9Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovascular Research. 2001 February 16, 2001;49(3):507-521. DOI: http://dx.doi.org/10.1016/S0008-6363(00)00281-9Шурыгин МГ, Шурыгина ИА. Фактор роста фибробластов как стимулятор ангиогенеза при инфаркте миокарда. Бюллетень Сибирского отделения Российской академии медицинских наук. 2010;30(6):89-92. [Shurygin MG, Shurygina IA. Fibroblast growth factor as angiogenesis stimulator at myocardial infarction. Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences. 2010;30(6):89-92.]Шурыгин МГ, Шурыгина ИА. Фактор роста фибробластов как стимулятор ангиогенеза при инфаркте миокарда. Бюллетень Сибирского отделения Российской академии медицинских наук. 2010;30(6):89-92. [Shurygin MG, Shurygina IA. Fibroblast growth factor as angiogenesis stimulator at myocardial infarction. Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences. 2010;30(6):89-92.]Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine & growth factor reviews. 2005;16(2):159-178. DOI: http://dx.doi.org/10.1016/j.cytogfr.2005.01.004Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine & growth factor reviews. 2005;16(2):159-178. DOI: http://dx.doi.org/10.1016/j.cytogfr.2005.01.004Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiological Reviews. 1993 January 1, 1993;73(1):161-195.Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiological Reviews. 1993 January 1, 1993;73(1):161-195.Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Molecular Biology of the Cell. 1993 October 1, 1993;4(10):973-982. DOI: http://dx.doi.org/10.1091/mbc.4.10.973Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Molecular Biology of the Cell. 1993 October 1, 1993;4(10):973-982. DOI: http://dx.doi.org/10.1091/mbc.4.10.973Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory Process in Type 2 Diabetes. Annals of the New York Academy of Sciences. 2006;1084(1):89-117. DOI: http://dx.doi.org/10.1196/annals.1372.039Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory Process in Type 2 Diabetes. Annals of the New York Academy of Sciences. 2006;1084(1):89-117. DOI: http://dx.doi.org/10.1196/annals.1372.039Подгребельный АН, Смирнова ОМ, Дедов ИИ. Роль фибробластов в развитии сахарного диабета и его осложнений. Проблемы эндокринологии. 2005;51(2):14-22. [Podgrebel'nyy AN, Smirnova OM, Dedov II. Rol' fibroblastov v razvitii sakharnogo diabeta i ego oslozhneniy. Problemy endokrinologii. 2005;51(2):14-22.]Подгребельный АН, Смирнова ОМ, Дедов ИИ. Роль фибробластов в развитии сахарного диабета и его осложнений. Проблемы эндокринологии. 2005;51(2):14-22. [Podgrebel'nyy AN, Smirnova OM, Dedov II. Rol' fibroblastov v razvitii sakharnogo diabeta i ego oslozhneniy. Problemy endokrinologii. 2005;51(2):14-22.]Portero-Otín M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, et al. Advanced Glycation End Product Precursors Impair Epidermal Growth Factor Receptor Signaling. Diabetes. 2002 May 1, 2002;51(5):1535-1542. DOI: http://dx.doi.org/10.2337/diabetes.51.5.1535Portero-Otín M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, et al. Advanced Glycation End Product Precursors Impair Epidermal Growth Factor Receptor Signaling. Diabetes. 2002 May 1, 2002;51(5):1535-1542. DOI: http://dx.doi.org/10.2337/diabetes.51.5.1535Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Laboratory investigation; a journal of technical methods and pathology. 2007 Sep;87(9):858-870. DOI: http://dx.doi.org/10.1038/labinvest.3700654Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Laboratory investigation; a journal of technical methods and pathology. 2007 Sep;87(9):858-870. DOI: http://dx.doi.org/10.1038/labinvest.3700654Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M-J, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European heart journal. 2007 January 1, 2007;28(1):88-136. DOI: http://dx.doi.org/10.1093/eurheartj/ehl260Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M-J, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European heart journal. 2007 January 1, 2007;28(1):88-136. DOI: http://dx.doi.org/10.1093/eurheartj/ehl260A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes. New England Journal of Medicine. 1996;335(11):775-782. DOI: http://dx.doi.org/10.1056/NEJM199609123351103A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes. New England Journal of Medicine. 1996;335(11):775-782. DOI: http://dx.doi.org/10.1056/NEJM199609123351103King DE, Mainous AG, Buchanan TA, Pearson WS. C-Reactive Protein and Glycemic Control in Adults With Diabetes. Diabetes Care. 2003 May 1, 2003;26(5):1535-1539. DOI: http://dx.doi.org/10.2337/diacare.26.5.1535King DE, Mainous AG, Buchanan TA, Pearson WS. C-Reactive Protein and Glycemic Control in Adults With Diabetes. Diabetes Care. 2003 May 1, 2003;26(5):1535-1539. DOI: http://dx.doi.org/10.2337/diacare.26.5.1535Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart. European heart journal. 2004 November 1, 2004;25(21):1880-1890. DOI: http://dx.doi.org/10.1016/j.ehj.2004.07.027Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart. European heart journal. 2004 November 1, 2004;25(21):1880-1890. DOI: http://dx.doi.org/10.1016/j.ehj.2004.07.027Барбараш ОЛ, Авраменко ОЕ, Осокина АВ, Сумин АН, Веремеев АВ. Роль провоспалительных факторов в оценке прогноза больных с прогрессирующей стенокардией в сочетании с сахарным диабетом 2 типа. Сахарный диабет. 2012;4:39–45. [Barbarash OL, Avramenko OE, Osokina AV, Sumin AN, Veremeev A. Prognostic significance of proinflammatory factors in patients with progressive angina pectoris and type 2 diabetes mellitus. Diabetes mellitus. 2012;4:39-45.]Барбараш ОЛ, Авраменко ОЕ, Осокина АВ, Сумин АН, Веремеев АВ. Роль провоспалительных факторов в оценке прогноза больных с прогрессирующей стенокардией в сочетании с сахарным диабетом 2 типа. Сахарный диабет. 2012;4:39–45. [Barbarash OL, Avramenko OE, Osokina AV, Sumin AN, Veremeev A. Prognostic significance of proinflammatory factors in patients with progressive angina pectoris and type 2 diabetes mellitus. Diabetes mellitus. 2012;4:39-45.]Подгребельный АН, Смирнова ОМ, Дедов ИИ, Ильин АВ, Никанкина ЛВ, Котельников МВ, Чернядьева ЮИ, Сунцов ЮИ. Атеросклероз и факторы роста (TGFb и bFGF) у пациентов с сахарным диабетом типа 2. Сахарный диабет. 2005;1:26-29. [Podgrebel'nyj A.N., Smirnova O.M., Dedov I.I., Il’in A.V., Nikankina L.V., Kotel'nikov M.V., Chernjad'eva Ju.I., Suntsov Y.I. Ateroskleroz i faktory rosta (TGFBL i BFGF) u patsientov s sakharnym diabetom tipa 2. Diabetes mellitus. 2005;1:26-29.]Подгребельный АН, Смирнова ОМ, Дедов ИИ, Ильин АВ, Никанкина ЛВ, Котельников МВ, Чернядьева ЮИ, Сунцов ЮИ. Атеросклероз и факторы роста (TGFb и bFGF) у пациентов с сахарным диабетом типа 2. Сахарный диабет. 2005;1:26-29. [Podgrebel'nyj A.N., Smirnova O.M., Dedov I.I., Il’in A.V., Nikankina L.V., Kotel'nikov M.V., Chernjad'eva Ju.I., Suntsov Y.I. Ateroskleroz i faktory rosta (TGFBL i BFGF) u patsientov s sakharnym diabetom tipa 2. Diabetes mellitus. 2005;1:26-29.]Celec P, Hodosy J, Jáni P, Janega P, Kúdela M, Kalousová M, et al. Advanced glycation end products in myocardial reperfusion injury. Heart Vessels. 2012 2012/03/01;27(2):208-215. DOI: http://dx.doi.org/10.1007/s00380-011-0147-zCelec P, Hodosy J, Jáni P, Janega P, Kúdela M, Kalousová M, et al. Advanced glycation end products in myocardial reperfusion injury. Heart Vessels. 2012 2012/03/01;27(2):208-215. DOI: http://dx.doi.org/10.1007/s00380-011-0147-zvan Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, et al. Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension. Circulation. 2008 January 1, 2008;117(1):43-51. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.107.728550van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, et al. Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension. Circulation. 2008 January 1, 2008;117(1):43-51. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.107.728550
The authors declare that there are no conflicts of interest present.